Publications by authors named "Philip Chamberlain"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

3,102

Total Likes

505

Extended Reach

253,243

Social Features

65
D
Discovery of Potent and Selective BCL6 Ligand-Directed Degrader (LDD), BCL6-760.
Hunter P Shunatona, Natalie Holmberg Douglas, Jayce Rhodes, William Thomas, Diogo Da Silva, Philip P Chamberlain

J Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular glue CELMoD compounds are regulators of cereblon conformation.
Edmond R Watson, Scott Novick, Mary E Matyskiela, Philip P Chamberlain, Andres H de la Peña

Science· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates.
Joel W Thompson, Thomas Clayton, Gody Khambatta, Leslie A Bateman, Christopher W Carroll, Philip P Chamberlain

Methods Mol Biol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the human marker of self 5-transmembrane receptor CD47.
Gustavo Fenalti, Nicolas Villanueva, Mark Griffith, Barbra Pagarigan, Sirish Kaushik Lakkaraju, Philip P Chamberlain

Nat Commun· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Aline Renneville, Jessica A Gasser, Daniel E Grinshpun, Pierre M Jean Beltran, Namrata D Udeshi, Philip P Chamberlain

Blood Cancer Discov· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Christine Surka, Liqing Jin, Nathan Mbong, Chin-Chun Lu, In Sock Jang, Philip Chamberlain

Blood· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons.
Mary E Matyskiela, Jinyi Zhu, Joshua M Baughman, Thomas Clayton, Michelle Slade, Philip P Chamberlain

ACS Chem Biol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
Mary E Matyskiela, Thomas Clayton, Xinde Zheng, Christopher Mayne, Eileen Tran, Philip P Chamberlain

Nat Struct Mol Biol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.
Philip P Chamberlain, Laura A D'Agostino, J Michael Ellis, Joshua D Hansen, Mary E Matyskiela

ACS Med Chem Lett· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of targeted protein degradation therapeutics.
Philip P Chamberlain, Lawrence G Hamann

Nat Chem Biol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cereblon modulators: Low molecular weight inducers of protein degradation.
Philip P Chamberlain, Brian E Cathers

Drug Discov Today Technol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Protein Degradation for Kinase Selectivity.
Philip P Chamberlain

Cell Chem Biol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.
Mary E Matyskiela, Suzana Couto, Xinde Zheng, Gang Lu, Julia Hui, Philip P Chamberlain

Nat Chem Biol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UBE2G1 governs the destruction of cereblon neomorphic substrates.
Gang Lu, Stephanie Weng, Mary Matyskiela, Xinde Zheng, Wei Fang, Philip Chamberlain

Elife· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Mary E Matyskiela, Weihong Zhang, Hon-Wah Man, George Muller, Godrej Khambatta, Philip P Chamberlain

J Med Chem· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
Jennifer R Riggs, Mark Nagy, Jan Elsner, Paul Erdman, Dan Cashion, Philip P Chamberlain

J Med Chem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Gregory D Ferguson, Mercedes Delgado, Veronique Plantevin-Krenitsky, Kristen Jensen-Pergakes, R J Bates, Philip Chamberlain

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Mary E Matyskiela, Gang Lu, Takumi Ito, Barbra Pagarigan, Chin-Chun Lu, Philip P Chamberlain

Nature· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Jan Krönke, Emma C Fink, Paul W Hollenbach, Kyle J MacBeth, Slater N Hurst, Philip P Chamberlain

Nature· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Philip Chamberlain, Silvia Delker, Barbra Pagarigan, Afshin Mahmoudi, Pilgrim Jackson

PLoS One· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Philip P Chamberlain, Antonia Lopez-Girona, Karen Miller, Gilles Carmel, Barbra Pagarigan

Nat Struct Mol Biol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.
Véronique Plantevin Krenitsky, Mercedes Delgado, Lisa Nadolny, Kiran Sahasrabudhe, Leticia Ayala, Philip Chamberlain

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.
Véronique Plantevin Krenitsky, Lisa Nadolny, Mercedes Delgado, Leticia Ayala, Steven S Clareen, Philip Chamberlain

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
Jingshan Ren, Philip P Chamberlain, Anna Stamp, Steven A Short, Kurt L Weaver

J Med Chem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis